Health Journal Online

Tag: risk

  • Lyme Disease Is Spreading into States That Rarely Saw It Before — Is Your County at Risk?

    Lyme Disease Is Spreading into States That Rarely Saw It Before — Is Your County at Risk?

    Lyme disease was once thought of as a problem concentrated in the Northeast and a few Midwest states. That geographic assumption is no longer accurate. Deer ticks — the primary carrier of the Lyme disease bacterium — are now establishing themselves in Ohio, Indiana, Illinois, and Michigan, areas where they were rarely found just a generation ago.

    Emergency department visits for tick bites were up more than 25 percent in April 2026 compared to April 2025, according to CDC data cited at a Johns Hopkins Bloomberg School of Public Health media briefing on May 5, 2026. Researchers called it an early signal of what could be a challenging year ahead.

    Why This Matters

    Lyme disease is the most common vector-borne illness in the United States, and it is underreported by a wide margin. State health departments reported more than 89,000 confirmed cases to the CDC in 2023 — the most recent year for which national data were published, but researchers estimate the true number is closer to half a million annually, largely because of misdiagnosis and underreporting in areas where the disease is newly arriving.

    For residents of expanding-risk states, this matters in a very practical way: your doctor, your local emergency room, and even the diagnostic tests used to confirm Lyme disease may not be calibrated to a disease that was once considered rare in your area. Early Lyme disease is treatable with antibiotics, but a delayed diagnosis can lead to more serious complications, including neurological and cardiac involvement.

    What We Know So Far

    The Companion Animal Parasite Council’s 2026 annual forecast — which tracks tick populations and disease risk — identifies Ohio, Kentucky, West Virginia, Tennessee, North Carolina, Indiana, Illinois, and Michigan as projected areas of significant Lyme disease expansion. The forecasts have historically been 94 percent accurate when compared to actual diagnostic results.

    The Upper Midwest and Northeast remain the highest-risk regions overall, with Minnesota, Wisconsin, Pennsylvania, New York, New Jersey, and Connecticut continuing to account for the largest share of confirmed cases. But the expansion is moving steadily south and west.

    According to Contagion Live, Dr. Elitza Theel, a Mayo Clinic infectious disease microbiologist, noted that “these cases have progressively spread into more Midwest states, such as Ohio, Pennsylvania, Indiana, and Illinois,” and attributed the spread to both tick range expansion and the proliferation of environmental reservoirs — particularly white-footed mice and deer.

    Where the Risk Is Highest

    Pennsylvania remains among the highest-burden states in the nation for both Lyme disease and related tick-borne conditions. The state is also now formally tracking cases of alpha-gal syndrome — a rare red meat allergy triggered by tick bites from the lone star tick — adding another dimension to tick-related health risk.

    Within the broader risk map, the CAPC forecast projects that some of the greatest expansions in Lyme disease risk in 2026 will occur in Ohio, Kentucky, West Virginia, and parts of Tennessee and North Carolina — states that until recently saw very few cases. Iowa is also identified as a higher-than-normal risk area, particularly in the southeastern part of the state, due to forested river corridors along the Mississippi and Iowa rivers.

    In Indiana, blacklegged ticks have now been found in almost every county, according to Purdue University’s Medical Entomology program. The tick was first discovered in the state of northwestern Indiana in 1987 and has since expanded rapidly.

    What Doctors and Experts Say

    Dr. Thomas Hart, an infectious disease microbiologist at the Johns Hopkins Bloomberg School of Public Health’s Lyme and Tick-Borne Diseases Research and Education Institute, explained the environmental drivers at the May 2026 briefing: “This increase in tick populations is going to be caused primarily by climate change. Warmer, milder winters are great for ticks to survive to the next year without freezing. And it also helps the animals that the ticks feed on — deer and mice — survive at greater populations.”

    Dr. Nicole Baumgarth, a Bloomberg Distinguished Professor at Johns Hopkins, noted that suburban expansion into wooded areas is another key contributor: human activity is increasingly bringing people into contact with tick habitat that was previously less accessible.

    What the Evidence Shows — and What It Does Not

    Researchers at Johns Hopkins have noted a well-documented challenge that comes with geographic expansion: diagnostic gaps. Lyme disease is confirmed using a blood test that detects antibodies, but antibodies may take several weeks to develop after infection. A test done too early can come back negative even in an infected patient.

    This limitation matters more in newly expanding regions, where physicians are less accustomed to suspecting Lyme as a diagnosis, and patients are less likely to report a tick bite as a relevant medical history item.

    Established science shows that early Lyme disease, caught within days to a few weeks of a tick bite, responds well to oral antibiotics. Later-stage disease — which can involve the joints, heart, and nervous system — requires more intensive treatment and may have lingering symptoms even after treatment is complete.

    Who Faces the Greatest Risk?

    People most at risk for Lyme disease in 2026 include:

    • Outdoor workers in landscaping, forestry, agriculture, and construction in the Northeast and expanding Midwest
    • Hikers, campers, hunters, and people who spend time in wooded or grassy areas
    • Children between 5 and 15 years old, who show consistently higher case rates in national surveillance
    • Adults between 45 and 55, the other age group with elevated case rates
    • Residents of newly endemic counties in Ohio, Indiana, Illinois, and Michigan who may not recognize tick exposure as a health concern
    • Pet owners whose dogs spend time outdoors and can carry ticks into the home

    Symptoms and Warning Signs to Watch For

    Early Lyme disease — within the first three to 30 days after a tick bite — may cause:

    • A bull’s-eye rash (erythema migrans) at the bite site, though this rash does not appear in all cases
    • Fever, chills, and fatigue
    • Muscle and joint aches
    • Headache
    • Swollen lymph nodes

    Later symptoms, if the infection goes untreated, may include severe joint pain and swelling, neurological problems such as facial palsy or numbness, heart rhythm irregularities, and cognitive difficulties.

    Contact a health care provider promptly if you find an attached tick, develop a rash near a bite site, or experience fever and fatigue following outdoor activity in a tick-prone area.

    What You Can Do Now

    • Use EPA-registered insect repellents with DEET (20–30 percent), picaridin, or IR3535 on exposed skin when outdoors in wooded or grassy areas.
    • Wear long sleeves and pants, and tuck pants into socks when hiking in tick habitat.
    • Perform a full-body tick check — including scalp, behind the ears, under the arms, and between the legs — after any outdoor activity.
    • Remove attached ticks promptly using fine-tipped tweezers, pulling upward with steady pressure. Do not twist or crush the tick.
    • Shower within two hours of coming indoors after outdoor activity.
    • Talk to your veterinarian about tick prevention for dogs, which can also bring ticks into your home.
    • If you find an attached tick or develop symptoms after potential exposure, contact a clinician. Do not wait for the rash — not everyone with Lyme disease develops the classic bull’s-eye pattern.

    Cost and Access: What Patients Should Know

    Standard Lyme disease testing is typically covered by health insurance, though the two-step testing protocol may require a laboratory order and follow-up confirmatory testing. Patients in newly expanding areas who suspect tick exposure should be specific with their health care provider about their outdoor activities and location.

    In areas with limited primary care access, telehealth can be a practical option for initial evaluation and a discussion of whether testing and empiric treatment are warranted. Oral antibiotics such as doxycycline, amoxicillin, and cefuroxime are effective for early Lyme disease and are widely available and relatively low-cost in generic form.

    What Happens Next

    The 2026 tick season is expected to remain active through October in most of the affected region. Researchers at Johns Hopkins are continuing work on Lyme disease diagnostics and are monitoring a pipeline of Lyme vaccines, though none is currently approved for human use in the United States. Updated CDC case data for 2024 are expected to be published later in 2026 and may confirm the geographic expansion already visible in tick surveillance data.

    The Bottom Line

    Lyme disease is no longer confined to the Northeast. If you live in Ohio, Indiana, Illinois, Michigan, or other expanding-risk areas, the risk of tick exposure in 2026 is meaningfully higher than it was just a few years ago. The best protection is simple and well-established: repellent, protective clothing, prompt tick checks, and early medical attention if you develop symptoms after possible tick exposure. Do not wait for the classic bull’s-eye rash, which is absent in a meaningful share of cases.

    References

    Source link

  • GLP-1 Drugs Like Ozempic Are Showing a 47 Percent Reduction in Breast Cancer Risk in a Major New Study — and Weight Loss May Not Explain It

    GLP-1 Drugs Like Ozempic Are Showing a 47 Percent Reduction in Breast Cancer Risk in a Major New Study — and Weight Loss May Not Explain It

    The list of conditions that GLP-1 receptor agonists appear to protect against keeps getting longer. These drugs — which include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and the newly approved orforglipron (Foundayo) — were originally developed for type 2 diabetes before emerging as transformative obesity medications. Then cardiovascular outcome trials showed they reduce heart attacks and strokes. Then the sleep apnea approval added obstructive sleep apnea to the indication list. Then studies suggested reductions in kidney disease progression, non-alcoholic fatty liver disease, and alcohol dependence.

    And now, a major study presented at the American Society of Clinical Oncology Annual Meeting in Chicago in early June 2026 and reported widely on June 10, 2026 has added breast cancer to the rapidly expanding list of conditions that GLP-1 drugs appear to protect against — with an effect magnitude that has stunned the oncology community.

    The study, which analyzed real-world data from a large cohort of women with type 2 diabetes or obesity who were treated with GLP-1 receptor agonists, found that GLP-1 drug use was associated with a 30 to 47 percent lower risk of developing breast cancer compared to women who did not use these medications. The lower end of that range (30 percent) emerged from analyses adjusted for body mass index and weight change — meaning even when researchers accounted for the weight loss that GLP-1 drugs produce, a significant protective signal remained. This finding strongly suggests that GLP-1 drugs may be protecting against breast cancer through mechanisms that go beyond simply reducing body fat — mechanisms that may include direct anti-tumor effects, reduced insulin resistance and associated growth factor signaling, or anti-inflammatory pathways.

    Why This Finding Is Biologically Plausible

    The biological connection between metabolic dysfunction, obesity, insulin resistance, and breast cancer risk is well established. Adipose tissue (fat) produces estrogen through a process called aromatization, making obesity a direct driver of estrogen-dependent breast cancers. Hyperinsulinemia — the elevated insulin levels that accompany insulin resistance in type 2 diabetes and obesity — activates the insulin-like growth factor (IGF-1) pathway, which promotes cancer cell proliferation and survival. Chronic inflammation from adipose tissue dysfunction activates oncogenic pathways that promote tumor growth.

    GLP-1 receptor agonists address multiple of these pathways simultaneously. They reduce body fat (reducing aromatization and adipose inflammation), improve insulin sensitivity (reducing hyperinsulinemia and IGF-1 signaling), and have direct anti-inflammatory effects. Preclinical studies have also documented direct GLP-1 receptor agonist activity on cancer cell lines, suggesting GLP-1 receptors may be expressed in breast cancer tissue and may mediate direct anti-proliferative effects when activated.

    The study’s finding that the protective signal persists even after adjustment for weight and BMI is the most provocative result, because it suggests the drug’s biological effects — beyond simple caloric restriction and fat mass reduction — are contributing to cancer protection.

    What This Means for the 15 Million Americans on GLP-1 Drugs

    Approximately 15 million Americans are currently prescribed GLP-1 receptor agonists. The vast majority are taking them for type 2 diabetes or weight management. If the breast cancer protective signal seen in this study is confirmed in larger prospective trials and in controlled analyses, it would represent an additional major health benefit of these medications — one that could influence prescribing decisions, insurance coverage arguments, and cancer prevention discussions.

    The researchers caution that this is observational data from a real-world cohort, not a randomized controlled trial. Confounding variables — the possibility that GLP-1 drug users differ from non-users in ways that independently affect breast cancer risk — must be accounted for before these findings can be considered definitive. Prospective studies and potential randomized trials with cancer outcomes as endpoints are now being planned. The Phase 3 ORCA trial of semaglutide in high-risk cancer prevention populations is one ongoing effort that will provide higher-quality evidence.

    For women currently taking GLP-1 drugs for any indication, this study is not a recommendation to take them as cancer prevention without diabetes or obesity indication — rather, it is an important signal that the health benefits of these medications may be broader than previously understood.

    Frequently Asked Questions

    Q: What did the new GLP-1 and breast cancer study find?

    A: A real-world cohort study presented at ASCO 2026 found that women with type 2 diabetes or obesity who used GLP-1 receptor agonists had a 30–47% lower breast cancer risk compared to non-users. The effect persisted after adjustment for weight loss.

    Q: Does this mean women should take GLP-1 drugs specifically to prevent breast cancer?

    A: No. This is observational data, not a randomized trial. The finding is a promising signal that warrants further research, not a clinical recommendation for GLP-1 drugs as cancer prevention outside of established indications.

    Q: Why might GLP-1 drugs protect against breast cancer beyond weight loss?

    A: By reducing hyperinsulinemia, improving insulin sensitivity (lowering IGF-1 signaling), reducing adipose-tissue inflammation, and potentially through direct GLP-1 receptor activity on breast tissue — all mechanisms independent of weight loss.

    Q: Which GLP-1 drugs were included in the study?

    A: The study analyzed GLP-1 receptor agonist use broadly, including semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) among the most commonly used agents. Results were not limited to a specific drug within the class.

    Q: How does this new finding fit with the other cancer data on GLP-1 drugs?

    A: A 2024 Nature Medicine study documented lower incidence of multiple obesity-associated cancers in GLP-1 users. The 2026 ASCO breast cancer study adds specifically to that growing body of evidence suggesting GLP-1 drugs may have broad anti-cancer properties.

    Source link

  • Chikungunya Outbreaks Are Now Active in Three Different Countries and Territories Simultaneously — and Summer Travelers Are at Risk from the Caribbean to the Indian Ocean

    Chikungunya Outbreaks Are Now Active in Three Different Countries and Territories Simultaneously — and Summer Travelers Are at Risk from the Caribbean to the Indian Ocean

    Summer 2026 has produced an unusual public health picture on the CDC Travel Health Notices page: three simultaneous active travel notices for chikungunya — the mosquito-borne virus known for causing weeks of debilitating joint pain — across three different geographic regions. Suriname, a country on the northeastern coast of South America, has had an active chikungunya outbreak since February 2026. Mayotte, a French territory in the Indian Ocean off the coast of Mozambique, has been under a CDC chikungunya notice since March 10, 2026. And French Guiana, the French overseas territory on the northern coast of South America adjacent to Brazil, received a new CDC travel notice for chikungunya on June 4, 2026 — just 10 days ago.

    Three simultaneous active outbreaks across two continents and the Indian Ocean, all in destinations that receive American travelers during peak summer season, all involving the same virus, and all preventable by a vaccine that most American travelers have never heard of.

    Chikungunya is caused by the chikungunya alphavirus, transmitted primarily by Aedes aegypti and Aedes albopictus mosquitoes — the same species responsible for dengue fever and Zika virus transmission. It cannot spread person to person. It requires a mosquito bite for transmission, which means travelers who effectively prevent mosquito bites can protect themselves. But unlike dengue — for which no reliably effective, widely available vaccine existed in the U.S. until recently — chikungunya now has an FDA-approved single-dose vaccine that provides broad, durable protection.

    The Pattern of These Three Simultaneous Outbreaks

    The geographic distribution of the three current CDC chikungunya notices reflects distinct but parallel epidemiological situations. In Suriname, chikungunya has been circulating since at least February 2026, consistent with the country’s tropical climate that supports year-round Aedes mosquito activity. Suriname borders Guyana to the west, Brazil to the south, and French Guiana to the east — meaning outbreak activity in Suriname creates risk for cross-border spread to adjacent territories, and the French Guiana notice issued June 4 is likely connected to regional transmission dynamics that began in Suriname and Brazil.

    Mayotte’s chikungunya outbreak is separate in origin — the island’s subtropical Indian Ocean climate creates independent conditions for Aedes activity, and chikungunya has a well-documented history of large outbreak cycles in Indian Ocean territories, including the catastrophic 2005–2006 outbreak in La Réunion that infected nearly one-third of the island’s population.

    What these three outbreaks share is the presence of Aedes aegypti or Aedes albopictus at epidemic transmission levels, a population of susceptible individuals without prior immunity, and the current arrival of the summer travel season, which increases the probability of importation to the United States via returning travelers.

    What Chikungunya Does to the Human Body

    The word chikungunya comes from the Makonde language of Tanzania, meaning “that which bends up” — a reference to the stooped posture that patients adopt in response to severe joint pain. The description is medically accurate and experientially unforgettable. After an incubation period of 2 to 12 days following a mosquito bite, patients develop sudden high fever — often above 103°F — accompanied by polyarthralgia, the simultaneous severe painful inflammation of multiple joints. The hands, wrists, ankles, and feet are most commonly affected, and the pain is frequently described by patients as worse than anything they have experienced. Many cannot walk, dress, or grip a cup.

    The acute phase typically lasts 7 to 10 days. Most patients recover. But approximately 25 to 50 percent of people infected with chikungunya develop chronic post-chikungunya arthritis — persistent joint pain that continues for months to years after the initial infection has resolved. This is the longest-lasting and most debilitating consequence of chikungunya, and it disproportionately affects older adults and those with pre-existing joint disease.

    The Vaccine That Travelers Are Not Getting

    The FDA approved Ixchiq (chikungunya vaccine) in November 2023 for adults 18 and older at increased risk of chikungunya exposure. Ixchiq is a live-attenuated, single-dose vaccine that requires no booster and has demonstrated strong immunogenicity and an acceptable safety profile in clinical trials. It is available through travel medicine clinics and many primary care providers.

    Despite its approval, Ixchiq remains significantly underutilized among American travelers to chikungunya-endemic and outbreak-affected regions. Awareness of the vaccine’s existence is low among both patients and some general practitioners who do not specialize in travel medicine. Travelers heading to Suriname, French Guiana, Mayotte, or any of the many Caribbean and South American destinations currently experiencing elevated chikungunya activity should specifically ask about Ixchiq at their travel medicine consultation.

    The vaccine requires at least 28 days to induce full protection, so travelers should plan accordingly — those departing within 28 days should be advised to rely on intensive mosquito bite prevention while the vaccine becomes effective, or may not benefit from vaccination for their current trip. As with all mosquito-borne disease prevention, repellent use, protective clothing, air conditioning, and bed nets remain essential complements to vaccination.

    Frequently Asked Questions

    Q: Where are the current chikungunya outbreaks with CDC travel notices?

    A: As of June 2026, active CDC chikungunya travel notices cover Suriname (February 2026), Mayotte, a French Indian Ocean territory (March 10, 2026), and French Guiana (June 4, 2026).

    Q: What are the symptoms of chikungunya?

    A: Sudden high fever and severe polyarthralgia — simultaneous joint pain in multiple joints, especially the hands, wrists, ankles, and feet — beginning 2 to 12 days after a mosquito bite. The pain is frequently described as the worst the patient has ever experienced. Most cases resolve within 7 to 10 days, but 25–50% develop chronic joint pain lasting months to years.

    Q: Is there a vaccine for chikungunya?

    A: Yes. Ixchiq is an FDA-approved single-dose live-attenuated vaccine for adults 18 and older. It was approved November 2023 and is available at travel medicine clinics. It requires approximately 28 days to become fully effective.

    Q: Who should get vaccinated against chikungunya before travel?

    A: Adults 18 and older traveling to areas with active chikungunya transmission who will have outdoor exposure to mosquitoes. This currently includes travelers to Suriname, French Guiana, Mayotte, and other active outbreak areas.

    Q: How is chikungunya different from dengue fever?

    A: Both are transmitted by Aedes mosquitoes and cause fever. Chikungunya is distinguished by the severe arthralgia (joint pain) that dominates its clinical picture and can persist for months to years. Dengue more commonly causes a characteristic rash, severe headache, and potentially hemorrhagic complications.

    Source link

  • CDC June 2026 Health Outlook: COVID Summer Surge Risk, West Nile Early Season, and Salmonella Moringa Alert

    CDC June 2026 Health Outlook: COVID Summer Surge Risk, West Nile Early Season, and Salmonella Moringa Alert

    Public health surveillance data released by the CDC as of June 5, 2026 offers a mixed picture of the nation’s current disease burden heading into the height of summer. COVID-19 activity is very low nationally, RSV and influenza seasons have ended, and the emergency department burden from respiratory illness is at its lowest point of the year. But officials are tracking several developing concerns that warrant attention from residents, clinicians, and travelers over the coming weeks.

    COVID-19: Low Now, But a Summer Surge Is Possible in the South and West

    The CDC’s June 5 Respiratory Virus Data update confirms that COVID-19 activity is currently very low across the United States, with declining hospitalizations nationally over recent months. As of June 2, the CDC estimates COVID-19 infections are declining or likely declining in 41 states and growing in only 1 state, according to the agency’s epidemic trend models.

    However, the CDC’s 2026 COVID Summer Outlook specifically warns that regions which did not experience substantial COVID activity during the most recent winter months — particularly the South and West — are expected to see increases in summer. The pattern of summer COVID surges in these warmer regions has recurred in multiple years since 2020, driven by people moving indoors to escape heat and, in 2026, by the convergence of World Cup mass gatherings drawing large numbers of international visitors into cities across those exact regions.

    People at higher risk of severe COVID outcomes — adults 65 and older, immunocompromised individuals, and those with significant underlying health conditions — should remain aware of updated vaccine recommendations and discuss antiviral treatment eligibility (Paxlovid) with their physician if they test positive.

    West Nile Virus: An Unusually Early Season Beginning

    West Nile virus activity has been confirmed earlier in the 2026 season than in most prior years, raising concern that peak summer transmission — which typically occurs July through September — could be more intense than average. Positive mosquito pools were confirmed in San Antonio in May (unusually early), in Frisco, Texas in early June, and in New Orleans in early June. Louisiana’s public health response included helicopter-based aerial spraying over parts of New Orleans and surrounding parishes. California confirmed positive mosquito samples across six counties by early June.

    West Nile virus has no vaccine and no approved treatment. The CDC recommends using EPA-registered insect repellents containing DEET, picaridin, IR3535, or oil of lemon eucalyptus; wearing long-sleeved shirts and pants during peak mosquito hours (dusk to dawn); eliminating standing water around the home; and ensuring window and door screens are intact.

    Salmonella in Moringa Supplements: 119 Cases, 36 States

    The ongoing CDC alert on Salmonella in moringa leaf supplement products has expanded since initial publication in May 2026. As of the latest update, the outbreak has sickened at least 119 people in 36 states, hospitalized 32, and involves a drug-resistant strain of Salmonella linked to brands including Live it Up, TNVitamins, Doctor’s Pride, MOGO, and Why Not Natural. Anyone currently using a moringa supplement should check the FDA’s active recall list and stop use immediately if their product is on it.

    Frequently Asked Questions

    Q: What is COVID activity level in the U.S. right now?

    A: As of June 5, 2026, COVID activity is very low nationally. CDC estimates infections are declining in 41 states. However, summer surges are possible in South and West regions.

    Q: Is West Nile virus active this summer?

    A: Yes. Positive mosquito pools have been confirmed earlier than usual in 2026 in San Antonio, Frisco TX, New Orleans, and six California counties. The early season start suggests potential for above-average transmission in peak summer months.

    Q: What should I do about the Salmonella-moringa outbreak?

    A: Stop using any moringa supplement and check FDA.gov/recalls for your brand. The outbreak has sickened 119 people in 36 states, with a drug-resistant Salmonella strain linked to several supplement brands.

    Q: Who is most at risk from West Nile virus?

    A: Adults 60 and older and immunocompromised individuals face the highest risk of neuroinvasive West Nile disease. About 80% of West Nile infections cause no symptoms; approximately 1% cause severe neurological illness.

    Source link

  • A Persistent Pesticide Is Linked to Alzheimer’s Risk

    A Persistent Pesticide Is Linked to Alzheimer’s Risk

    How can we avoid the breakdown products of pesticides that may increase the risk of Alzheimer’s disease as much as if you carried APOE e4, the so-called Alzheimer’s gene?

    Although there is a growing list of Alzheimer’s disease susceptibility genes, those genes account for less than half of all Alzheimer’s cases. Here is the “single most compelling” piece of data on the potential control we have over the disease: When it comes to identical twins with the exact same genes, if one gets Alzheimer’s, the other usually does not. So, we have to think about all the other contributing factors beyond just genetics.

    There’s a list of chlorinated pesticides, including DDE (a metabolite of DDT), that the U.S. Environmental Protection Agency has classified as probable human carcinogens. But in a study—which I’ve mentioned in a video on pesticides and cancer—blood levels of DDE and other pesticides were associated not with increased cancer mortality, but increased risk of other-cause mortality. This led researchers to speculate that this may be due to an associated increased risk of diabetes or dementia. I’ve talked previously about the diabetes link. What about dementia?

    A research team at Rutgers found significantly higher blood levels of DDE in Alzheimer’s disease patients compared to controls, as you can see below and at 1:22 in my video Pesticides (DDT) and Alzheimer’s Disease.

    Autopsy studies show blood levels are a good proxy for brain levels. Those patients with the highest levels were at about four times the odds of having dementia from Alzheimer’s. And in a petri dish, DDE increases amyloid precursor protein levels in human brain cells, providing a potential mechanism. Below and at 1:48 in my video, you can see the levels of the sticky protein implicated in the development of Alzheimer’s disease before and after DDE is added at the levels one finds circulating in highly exposed individuals among the general population.

    Put all these studies together, and there does indeed seem to be a link, consistent with data showing about a doubling of risk for developing dementia among those acutely pesticide-poisoned, as you can see below and at 2:01 in my video.

    Among U.S. elders, DDT and its breakdown product DDE are also associated with increased risk of cognitive decline in general, which is shown below and at 2:08 in my video.

    DDT was used extensively in the United States from the 1940s through the early 1970s. At its peak, we were churning out about 180 million pounds a year. And it is still in our bodies to this day, contaminating the bloodstreams of more than 90% of Americans, with DDE—the pesticide linked to quadrupling the odds of Alzheimer’s—found at the highest levels of all.

    It’s still in our bodies because it’s still in the food supply. In a previous video on the topic, I noted that the levels of DDT, DDE, and other banned pesticides and pollutants were much lower in the breast milk from a vegetarian mother compared to breast milk of her non-vegetarian sister. The largest difference was noted for DDE, which was four times lower in the vegetarian sister. This is what you see across the board for these kinds of pollutants. Below and at 3:20 in my video, you can see the levels of dioxins and PCBs found in beef, chicken, pork, processed meat, eggs, fish, dairy products, and all plant foods put together when food samples were collected from supermarkets across the United States.

    These toxins build up in the food chain, so it makes sense that the most contaminated foods are meat, fish, and dairy products. The toxin levels were found to be 5 to 10 times higher in meat, eggs, fish, and dairy compared to plant foods. Unfortunately, cooking doesn’t destroy pollutants like DDE—in fact, it may make them even more concentrated. And this is for a pesticide that may increase the risk of Alzheimer’s disease as much as if you carried the so-called Alzheimer’s gene APOE e4.

    Doctor’s Note

    The video I mentioned is Pesticides and Cancer Risk.

    For more videos on Alzheimer’s disease, check out the Alzheimer’s topic page.



    Source link

  • Penn Medicine Reports 30% Drop in Breast Cancer Risk with Ozempic and Wegovy

    Penn Medicine Reports 30% Drop in Breast Cancer Risk with Ozempic and Wegovy

    A landmark study published June 2, 2026, in JCO Oncology Practice and simultaneously presented at the 2026 American Society of Clinical Oncology Annual Meeting by researchers at the University of Pennsylvania Perelman School of Medicine has produced findings that could reshape how America’s medical community thinks about GLP-1 receptor agonist drugs and how millions of women with obesity approach their own cancer risk.

    The study, led by Dr. Elizabeth McDonald, a professor of radiology at Penn and practicing breast radiologist at Penn’s Abramson Cancer Center, found that women using GLP-1 medications were approximately 30% less likely to develop breast cancer than women who were not taking these drugs. The finding comes from an analysis of 111,646 women, the largest study of its kind, and the protective effect held even after rigorous statistical matching to control for confounding factors.

    The scale and rigor of the Penn Medicine study are what elevate it above prior observational work in this area. Researchers used electronic health records from the University of Pennsylvania Health System, which includes both academic and community medical sites across Pennsylvania and New Jersey, to identify women aged 45 to 80 with a BMI of 25 or above who had undergone breast imaging between January 2022 and June 2025.

    Of the 111,646 women in the full cohort, 15,264 (13.7%) had documented GLP-1 medication prescriptions, and 96,382 (86.3%) had no documented GLP-1 exposure. The researchers examined cancer incidence in both the full cohort and a matched cohort of 30,528 women, pairing each GLP-1 user one-to-one with a control patient matched on age, race, ethnicity, BMI, breast density, and diabetes status.

    The result: 35.1% lower odds of breast cancer in the full analysis; 30.5% lower odds in the rigorously matched cohort.

    Why the 30% Reduction Is Scientifically Credible

    The breast cancer finding is consistent with what GLP-1 drugs do biologically. GLP-1 receptor agonists, the drug class that includes Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), and Zepbound (tirzepatide), produce significant weight loss and improve key metabolic measures such as insulin sensitivity, inflammation levels, and sex hormone balance. Each of these changes is independently linked to lower breast cancer risk through well-established biological pathways.

    Body fat is not just storage tissue; it is hormonally active. It converts androgens into estrogens through a process called aromatization. In postmenopausal women who are overweight or obese, fat tissue becomes the main source of circulating estrogen. Most breast cancers, about 70 to 75 percent, are estrogen receptor-positive, meaning they grow in response to estrogen. When weight is reduced, fat tissue decreases, aromatization declines, estrogen levels drop, and the growth stimulus for these cancers is reduced. This mechanism is widely accepted and helps explain why obesity increases breast cancer risk and why weight loss lowers it.

    GLP-1 drugs also reduce chronic low-grade inflammation, measured through markers such as CRP, which can contribute to a tumor-friendly environment. In addition, they improve insulin resistance, lowering levels of insulin and IGF-1, both of which have been shown to directly promote breast cancer cell growth.

    “While our study was observational and does not definitively confirm an association,” Dr. McDonald said, “it does add to the growing body of evidence suggesting that it’s worth investigating these weight-loss drugs as potential cancer prevention tools.”

    The Philadelphia Context: Penn Medicine, Penn’s Abramson Center, and What This Means Locally

    The Penn Medicine research carries particular significance in Philadelphia, where the study was conducted. The Penn Abramson Cancer Center, consistently ranked among the top cancer hospitals in the United States, is home to a major breast imaging and breast oncology program. The health system spans Pennsylvania and New Jersey, and the electronic health records used in the study reflect a real-world patient population in the greater Philadelphia region, including a wide range of body weight profiles, cancer risk factors, and GLP-1 prescribing patterns.

    Philadelphia County has a breast cancer incidence rate above the national average, driven in part by higher obesity rates among women, especially in lower-income areas of North, West, and South Philadelphia. If GLP-1 drugs reduce breast cancer risk by 30% in overweight and obese women, the same group that accounts for much of the county’s burden, the public health impact could be significant. Access becomes the key issue. The women most likely to benefit are also those most likely to face insurance and cost barriers to GLP-1 treatment.

    What Women Should Discuss with Their Doctors Now

    The Penn Medicine study is observational — it does not prove causality and does not constitute a clinical recommendation to prescribe GLP-1 drugs for breast cancer prevention. Breast cancer prevention currently relies on lifestyle modification, screening adherence, chemoprevention with tamoxifen or aromatase inhibitors for high-risk individuals, and prophylactic surgical options for those with BRCA mutations.

    What the study does justify is a conversation: women aged 45 to 80 who are overweight or obese, who are considering GLP-1 therapy for obesity or diabetes management, should ask their provider whether the breast cancer risk data adds weight to the clinical rationale for their treatment. For women who are already on GLP-1 medications, this study provides additional scientific support for the value of continued treatment. For oncologists, this data adds a new dimension to the patient conversation about weight management as cancer prevention — one with a specific drug class and a quantified risk reduction.

    Source link

  • How Big Is the Cancer Risk from Processed Meat?

    How Big Is the Cancer Risk from Processed Meat?

    I quantify the risks of colon and rectal cancers from eating bacon, ham, hot dogs, sausage, and lunch meat.

    In 2018, arguably the most prestigious cancer research institution in the world, the International Agency for Research on Cancer (IARC), part of the World Health Organization, published its report on processed meat, concluding that foods like bacon, ham, hot dogs, lunch meat, and sausage are cancer-causing, classifying processed meat as a Group 1 carcinogen. “These findings,” concluded the director of the agency, “further support current public health recommendations to limit intake of meat.” Critics questioned putting processed meat in the same carcinogenic classification as asbestos and tobacco. Or, as a pesticide company roughly put it, how can eating processed meat be in the same category as mustard gas?

    As I discuss in my video How Much Cancer Does Processed Meat Cause?, the classifications only relate to the strength of evidence that the agent causes cancer or not, not how much cancer. This doesn’t mean they all pose the same level of danger. It’s safer to eat a sandwich filled with pastrami than plutonium, even though they are both Group 1 carcinogens, which means both substances are known to cause cancer in people. So, just how dangerous is meat? The relative risk of colorectal cancer was 18% for every 50 grams eaten a day. But what exactly does that mean?

    Well, 50 grams is about one hot dog, or two breakfast links, or two slices of Canadian bacon or ham. So, a daily sandwich with one or two slices of baloney would increase your colorectal cancer risk by 18%. But a half-pound of pastrami on rye would bump it up more like 80%. Okay, but what does the 18% increased risk really mean? One way to look at it is absolute risk versus relative risk. Assuming that the lifetime risk of colorectal cancer is about 5% (1 in 20), increasing your risk by about 20% would only bump up your absolute risk of getting colorectal cancer from 5% to 6%. Now, on a population scale, an 18% drop in risk could mean about 25,000 fewer cases of colorectal cancer every year in the United States, 25,000 fewer families a year dealing with that diagnosis, if we swapped out the daily baloney sandwich for hummus or if we chose veggie dogs instead. So, it all depends on how you look at it.

    Colorectal cancer is the United States’ second leading cause of cancer death for men and women combined, after lung cancer. So, if you don’t smoke, colon and rectal cancer may be your greatest cancer nemesis. But we can drop the risk of getting it by about a fifth with a single dietary tweak: cutting a serving of processed meat out of our daily diet.

    How does 18% increased cancer risk compare to other risky behaviors? In my testimony before the Dietary Guidelines Scientific Committee, I made what may sound like a hyperbolic metaphor. I asked, “We try not to smoke around our kids, why would we send them to school with a baloney sandwich?” That is not hyperbole. According to the Surgeon General, living with a smoker increases our risk of lung cancer by 15%. So, breathing second-hand smoke day in and day out increases our risk of lung cancer almost as much as eating a serving of processed meat day in and day out increases our risk of colorectal cancer.

    The meat industry responded by saying that we must consider the risks together with the benefits before we tell people what to eat or breathe. Think about all the baloney benefits—lunch meat isn’t just about cancer, but convenience.

    Indeed, processed meat isn’t just about cancer. An article railing against the World Health Organization’s “meat terrorism” cited the Global Burden of Disease studies comparing how many cancer deaths are caused by processed meat consumption compared to tobacco or alcohol use. But if you look at the study they’re referencing, the roughly 37,000 deaths attributable to higher processed meat intake are just the colorectal cancer deaths and don’t also include the 100,000 deaths from diabetes or the 400,000 deaths from heart disease. So, in actuality, we may be talking about half a million deaths attributable to processed meat, as you can see below and at 4:06 in my video.

    And it’s not just colon and rectal cancer. If you look at the science since the IARC decision was published, processed meat may also increase the risk of prostate cancer, breast cancer, and pancreatic cancer.

    Unfortunately, research shows that “despite growing public health concerns about processed meat consumption, there have been no changes in the amount of processed meat consumed by US adults over the last 18 years.” Of course, it would have helped if the last Dietary Guidelines for Americans had happened to mention that processed meat was a carcinogen. Publishing “an explicit and science-based statement on processed meat” in the next Dietary Guidelines would certainly help. But the scientific committee made no such recommendation.

    Sadly, even those with colorectal cancer “hardly improve their overall lifestyle after diagnosis,” though that may be because “70% of cancer patients have never received nutrition advice from their [medical] providers during or after treatment.” That just blows me away.

    An article published in a scientific cancer-research journal stated that “despite the continued obfuscation of the issue by the meat industry—they learned well from the tobacco merchants—meat should continue to be a focus of public health action.” New York City is leading the way, passing legislation to ban processed meats from school meals. Not giving our kids carcinogens? What a concept!

    Meanwhile, the processed meat industry is trying to reformulate its products. It’s kind of like in the pharmaceutical area, where you try to mitigate the potential adverse effects of one drug by prescribing an additional drug. For example, fiber could be added to hot dogs to try to counterbalance the risk, potentially reducing the cancer load by changing how it’s processed instead of by banning processed meat altogether.

    Doctor’s Note

    If you missed the previous video, see IARC: Processed Meat Like Bacon Causes Cancer.

    For my full testimony on the U.S. Dietary Guidelines, check out Highlights from the 2020 Dietary Guidelines Hearing.



    Source link

  • Healthy Habits to Lower Your Risk and Protect Heart Health

    Healthy Habits to Lower Your Risk and Protect Heart Health

    High blood pressure often develops quietly, damaging blood vessels and increasing the risk of heart attack, stroke, and kidney disease. Many people do not notice symptoms until complications appear, which is why prevention matters early. The good news is that lifestyle choices can make a major difference in reducing risk and improving long-term heart health.

    Simple daily habits such as better nutrition, regular movement, healthy sleep, and stress control can help lower blood pressure naturally. Small changes done consistently often lead to measurable results over time. With the right routine, hypertension prevention becomes more achievable and sustainable for people of all ages.

    7 Essential Habits to Prevent High Blood Pressure

    Preventing high blood pressure often starts with simple daily choices that protect your heart over time. These seven essential habits can help lower your risk, improve circulation, and support long-term heart health naturally.

    1. Follow the DASH Diet

    The DASH diet is one of the most effective eating plans to prevent high blood pressure by focusing on fruits, vegetables, whole grains, beans, nuts, and low-fat dairy. Limiting sugary drinks, red meat, and processed foods while adding potassium-rich foods like bananas and spinach can support lower blood pressure and better heart health.

    2. Get Regular Aerobic Exercise

    Walking, cycling, swimming, and jogging can help lower blood pressure naturally when done consistently. Aim for at least 150 minutes of moderate aerobic exercise weekly to improve circulation, reduce stress, and support weight control.

    3. Maintain a Healthy Weight

    Carrying extra body weight increases strain on the heart and blood vessels, which may raise blood pressure over time. Losing even a small amount of weight through healthy eating and activity can improve readings and support hypertension prevention.

    4. Reduce Sodium Intake

    Too much sodium can raise blood pressure in many adults, especially when intake is frequent and high. Choosing fresh foods, reading labels, and seasoning meals with herbs or lemon instead of salt can help reduce sodium levels.

    5. Manage Stress Daily

    Chronic stress may contribute to unhealthy blood pressure patterns and long-term heart strain. Mindfulness, breathing exercises, journaling, or yoga can help lower stress while supporting better sleep and wellness.

    6. Improve Sleep Quality

    Poor sleep is linked with a higher risk of high blood pressure and cardiovascular problems. Aim for seven to nine hours of sleep nightly and maintain a regular schedule to improve overall health.

    7. Limit Alcohol and Avoid Smoking

    Too much alcohol may gradually increase blood pressure, while smoking damages blood vessels and strains the heart. Reducing alcohol intake and quitting smoking can quickly improve heart health and lower long-term risk.

    Prevent High Blood Pressure: Dietary Patterns and Food Choices

    Prevent high blood pressure by focusing on eating patterns rather than one “superfood.” The DASH diet and Mediterranean-style eating plans both emphasize vegetables, fruit, lean proteins, legumes, whole grains, and healthy fats. These approaches may support better blood pressure levels while improving cholesterol and overall heart health.

    According to the Centers for Disease Control and Prevention, reducing sodium, choosing healthier foods, and maintaining a healthy weight are key strategies for managing and preventing high blood pressure. Potassium-rich foods such as beans, leafy greens, potatoes, bananas, and yogurt can also support healthier blood pressure balance. Learn more at

    Meal timing can also help some people. Regular meals with balanced portions may support blood sugar stability and reduce overeating later in the day. Sustainable habits matter more than extreme restrictions.

    Hypertension Prevention: Exercise Protocols and Monitoring Strategies

    Hypertension prevention improves when exercise becomes part of a weekly routine. Moderate aerobic movement such as brisk walking for 30 to 45 minutes on most days can strengthen the heart and help lower blood pressure. Resistance training two to three times weekly may add further benefits.

    Based on guidance from the American Heart Association, regular physical activity is one of the most effective natural tools for lower blood pressure and heart health. Combining cardio exercise with strength training can improve circulation, body composition, and metabolic wellness. More guidance is available at

    Home blood pressure monitoring is also valuable. Use a validated device, measure at consistent times, and track trends rather than single readings. This can help identify patterns and motivate healthier habits.

    Heart Health: Sleep, Stress Reduction, and Long-Term Lifestyle Support

    Heart health depends on more than food and workouts. Sleep quality, emotional stress, and routine daily behaviors all influence blood pressure. Poor sleep and ongoing tension may keep the body in a heightened stress state that affects vascular function.

    Based on research from National Heart, Lung, and Blood Institute, sleep habits, stress management, and healthy routines are important parts of blood pressure control and cardiovascular wellness. Relaxation techniques such as deep breathing, meditation, and consistent sleep schedules may help support healthier readings. Learn more at

    Long-term success usually comes from stacking small habits rather than chasing quick fixes. Protecting heart health is often about what you repeat daily.

    Essential Heart Health Habits for Lifelong Blood Pressure Control

    High blood pressure prevention works best when healthy habits become part of everyday life. Eating better, moving regularly, sleeping well, managing stress, and avoiding tobacco all work together to reduce long-term risk. Even modest changes can create meaningful progress when maintained consistently.

    Lower blood pressure goals do not require perfection. What matters most is building routines that fit your lifestyle and can last for years. With patience and consistency, hypertension prevention becomes a realistic path toward stronger heart health and better overall wellbeing.

    Frequently Asked Questions

    1. Can high blood pressure be prevented naturally?

    Yes, many people can reduce risk through lifestyle habits. Healthy eating, exercise, sleep, and stress management all help. Avoiding smoking and excess alcohol also matters. Genetics can still play a role, so regular checkups remain important.

    2. What foods help lower blood pressure?

    Foods rich in potassium, fiber, and healthy fats may help. Examples include leafy greens, beans, oats, berries, yogurt, nuts, and fish. Lower-sodium choices are also helpful. Balanced eating patterns matter more than single foods.

    3. How much exercise helps blood pressure?

    A common target is 150 minutes of moderate activity weekly. This can include walking, biking, or swimming. Strength training can add benefits as well. Consistency matters more than intensity for many people.

    4. When should I see a doctor about blood pressure?

    See a doctor if readings stay elevated or symptoms concern you. Severe headaches, chest pain, or shortness of breath need prompt care. Regular monitoring helps catch issues early. Professional guidance is useful for personalized treatment plans.



    Source link

  • Hidden Gut Virus Inside a Common Bacterium May Double Colon Cancer Risk and Could Become a Future Stool-Based Screening Marker

    Hidden Gut Virus Inside a Common Bacterium May Double Colon Cancer Risk and Could Become a Future Stool-Based Screening Marker

    Hidden viruses in the gut are emerging as a new frontier in cancer research, and the virome may be just as important as bacteria when it comes to colorectal cancer risk. A newly described bacteriophage hiding inside common Bacteroides bacteria has been linked to roughly doubled odds of developing colorectal cancer, and it may one day serve as a non‑invasive stool biomarker for earlier detection.

    This finding is pushing scientists to look beyond bacteria alone and consider how viral communities in the intestine shape health and disease.

    Colorectal Cancer and the Need for Better Screening

    Colorectal cancer starts in the colon or rectum, usually from small polyps that can become malignant over many years.

    Because early stages often cause no symptoms, detection before spread is crucial for survival and treatment success. When found early, colorectal cancer is usually much more treatable and associated with better long‑term outcomes.

    Current screening tools include colonoscopy, sigmoidoscopy, fecal occult blood tests (FOBT/FIT), and stool DNA tests. Colonoscopy is highly effective but invasive, requires bowel preparation, and can be difficult to access for some people.

    Stool‑based tests are simpler and non‑invasive, but they can miss early cancers or advanced polyps. These limitations drive interest in new stool biomarkers, including those that come from the gut virome, bacteriophages, and specific Bacteroides strains.

    Microbiome, Virome, and Cancer Risk

    Most research on colorectal cancer and the gut has focused on the microbiome, the community of bacteria in the intestine. Studies repeatedly show that certain bacteria, such as Fusobacterium and some Bacteroides species, are more common in people with colorectal cancer than in healthy controls.

    These microbes may promote inflammation, produce toxins, or form biofilms that help tumors develop and escape immune defenses.

    Alongside bacteria, the gut also hosts a rich virome, made up largely of bacteriophages, viruses that infect bacteria, not human cells. Bacteriophages can integrate into bacterial genomes (as prophages) or lyse their hosts. In doing so, they can change which bacteria are present and how they behave.

    A bacterium carrying a particular prophage may produce more toxins, adhere more strongly to the gut lining, or interact differently with the immune system.

    Because of these effects, the virome is now seen as an important factor in colorectal cancer. Distinct bacteriophage patterns have been observed in stool samples from colorectal cancer patients.

    These patterns suggest that certain phages, especially those linked to Bacteroides, could act as both contributors to disease and as stool biomarkers that signal increased risk.

    Bacteroides fragilis and a Hidden Bacteriophage

    Bacteroides is a major bacterial genus in the human colon and plays key roles in digestion and immune development. Among its species, Bacteroides fragilis is widely present in healthy individuals.

    Most strains are harmless or beneficial, but some enterotoxigenic Bacteroides fragilis (ETBF) strains produce toxins that can cause diarrhea and chronic inflammation.

    Recent work has revealed a previously unrecognized bacteriophage integrated into Bacteroides fragilis genomes. In its prophage state, this virus sits quietly inside the bacterial DNA and is not visible as an active infection.

    Using high‑throughput sequencing of bacterial isolates and stool samples, researchers identified a specific viral sequence that appeared far more often in Bacteroides fragilis from people with colorectal cancer than in those without the disease.

    This suggests that the combination of Bacteroides and a particular bacteriophage may matter more than the bacterium alone.

    How Strong Is the Association With Colorectal Cancer?

    Across large international cohorts, individuals with colorectal cancer were about twice as likely to carry this Bacteroides‑associated bacteriophage compared with cancer‑free controls.

    This does not prove that the virus causes cancer, but it signals a strong association worth further study. It raises the possibility that the bacteriophage could affect bacterial virulence, toxin production, or interactions with the gut lining in ways that promote tumor development.

    Mechanistically, researchers suspect that prophage integration might alter gene regulation in Bacteroides fragilis, increase production of inflammatory or genotoxic factors, or encourage biofilm formation on the colon mucosa.

    Even if the virus itself is not directly oncogenic, it may mark a broader virome and microbiome shift that creates a more cancer‑prone environment. From a screening perspective, this kind of consistent association is valuable, because a reliable marker can help identify people at higher risk.

    Virome-Based Stool Biomarkers: A New Screening Frontier

    Stool is an ideal medium for non‑invasive testing because it contains DNA and RNA from bacteria, viruses, and the host. Traditional stool tests for colorectal cancer look for blood or human DNA mutations.

    Microbiome‑based approaches add information about bacterial composition. Virome‑based testing extends this by targeting bacteriophages and other gut viruses as additional indicators.

    Bacteriophages are attractive stool biomarkers because they are abundant and often highly specific to their bacterial hosts. A virome‑focused assay could, in principle, detect the Bacteroides‑associated bacteriophage linked to colorectal cancer.

    This could be done with broad metagenomic sequencing or with targeted PCR approaches that look specifically for the viral sequence.

    In real‑world use, such a viral marker would likely be combined with bacterial, human DNA, and blood‑based markers in a multi‑parameter stool test, improving sensitivity for early disease while maintaining acceptable false‑positive rates.

    Before any virome‑based stool biomarker becomes part of standard care, it must be validated in large prospective studies, tested across diverse populations, and shown to be cost‑effective and practical in routine clinics. Laboratory methods will need standardization, and regulatory approval will be required.

    Virome-Driven Advances in Colorectal Cancer Prevention

    The emerging link between the gut virome, specific bacteriophages, Bacteroides, and colorectal cancer underscores how complex the intestinal ecosystem is. As research continues, virome‑based stool biomarkers may complement colonoscopy and existing stool tests, offering more personalized and less invasive screening options.

    If the Bacteroides‑associated bacteriophage consistently identifies individuals at higher risk, an accessible stool biomarker built around this virome signal could help detect colorectal cancer earlier and guide timely prevention and treatment.

    Frequently Asked Questions

    1. Can changing my diet modify the gut virome and possibly affect colorectal cancer risk?

    A diet rich in fiber, fruits, and vegetables can shift both the microbiome and virome toward more diverse, stable communities, which is generally associated with lower inflammation and may indirectly reduce colorectal cancer risk.

    2. Is it possible to remove harmful bacteriophages like the one in Bacteroides with probiotics?

    Current probiotics mainly influence bacteria, not specific bacteriophages; while they might alter the overall ecosystem, there is no evidence yet that standard probiotic products selectively remove this Bacteroides‑associated virus.

    3. Could antibiotics help by eliminating Bacteroides strains carrying cancer‑linked bacteriophages?

    Broad antibiotics can reduce Bacteroides and associated phages, but they also disrupt beneficial microbes and may harm long‑term gut health, so they are not considered a targeted or preventive strategy for colorectal cancer.

    4. Are at-home microbiome tests able to detect virome patterns linked to colorectal cancer?

    Most consumer microbiome kits focus on bacterial DNA and do not comprehensively profile the virome, so they cannot reliably detect cancer‑associated bacteriophage signatures at this time.



    Originally published on Science Times

    Source link

  • Aligning Procurement with Clinical Risk Awareness

    Aligning Procurement with Clinical Risk Awareness

    Innovel Medical, a London-based developer of clinically focused medical technologies funded by Pentland Medical, presents a perspective that airway safety outcomes may be influenced by how procurement decisions are made. This consideration becomes particularly relevant when cost factors are prioritized over purpose-built securement solutions intended to support patient safety, infection control, and tube stability.

    “In operating rooms and critical care settings, airway securement is an important part of patient care that doesn’t always receive the same level of attention,” Stewart Munro, Managing Director of Innovel, states. “Clinicians recognize its role in maintaining stability during anesthesia and ventilation, though the approaches used in practice can vary.”

    The implications of this variability are increasingly supported by emerging data. According to a study, unplanned extubation (UE) remains a measurable and persistent safety concern, even as structured airway safety programs demonstrate the ability to reduce its incidence. These findings, Munro argues, point to a broader opportunity for consistency in airway management practices, particularly in how devices are selected and applied.

    “In many areas of medicine, practice evolves as evidence accumulates, yet airway securement has often relied on methods that were never originally designed for the task. There’s an opportunity to revisit these conventions with a more intentional lens,” he explains. Munro believes that unplanned extubation is preventable and encourages standardized securement approaches supported by reliable tools and protocols.

    Within clinical settings, Munro notes that the challenges associated with non-purpose-built securement methods can present in several ways. Clinicians may encounter variability in adhesive performance, which can affect tube stability during procedures involving movement or prolonged positioning. Skin integrity can also become a consideration, particularly among pediatric and older adult patients, where repeated application and removal of general-use tape can affect the skin barrier. These factors, while often managed at the bedside, contribute to a broader picture of cumulative clinical and operational impact.

    Research into ventilator-associated pneumonia (VAP) further illustrates the importance of secure airway management. A pneumonia surveillance guidance highlights the role of tube movement and micro-aspiration in bacterial contamination of the lower airway. A meta-analysis, encompassing more than 16,000 patients, found that re-intubation increased the risk of VAP by more than fivefold. Such findings, Munro stresses, reinforce the connection between airway stability and infection risk, underscoring the value of securement methods that can maintain consistency throughout the duration of care.

    Munro offers an additional perspective on how these clinical realities intersect with procurement practices. “When decisions are made primarily at the unit-cost level, it can be difficult to fully account for the downstream clinical considerations that follow. Expanding the lens to include total care impact allows for a more balanced evaluation,” he remarks. This viewpoint reflects a growing conversation among healthcare leaders and procurement teams about how to align purchasing decisions with broader patient safety and system efficiency goals.

    Innovel’s response to these insights is reflected in the development of LeaFix, a purpose-built airway securement device designed specifically for endotracheal applications. Engineered with a focus on both stability and skin compatibility, LeaFix incorporates a structured adhesive design that distributes pressure across anatomical anchor points, supporting consistent tube positioning. Its CE marking under the EU Medical Device Regulation (MDR) reflects adherence to stringent regulatory standards, providing an additional layer of assurance for healthcare providers seeking validated solutions and providing Innovel with real-world clinical evidence to improve its solution.

    Beyond its technical features, Innovel observes that LeaFix may reflect a growing recognition of airway securement as a distinct area within clinical practice. Munro states, “In other areas of care, purpose-built devices have often been introduced over time as understanding of clinical requirements and performance expectations has developed.”

    Within this context, Innovel’s broader portfolio, including complementary solutions such as packaging both eye and airway securement solutions together, is part of its ongoing focus on helping related needs across the airway management pathway. Another innovative solution from Innovel is the Vacuderm, which is a smart tourniquet with an aim to not only identify potential invisible veins, but also facilitate easier cannulation.

    The conversation around airway securement is also extending into professional forums and educational initiatives. Innovel has supported a recent webinar, where clinical experts shared insights into airway-related risks and emerging best practices. Such platforms, as Munro notes, can contribute to raising awareness and fostering dialogue among clinicians, hospital leaders, and policymakers.

    As healthcare systems continue to refine their approaches to patient safety, airway securement presents an opportunity for alignment between clinical insight, regulatory standards, and procurement strategy. Munro states, “Progress usually begins with recognizing areas that have remained unchanged for a long time. From there, meaningful improvements can be introduced through collaboration and thoughtful design.”

    A forward path emerges through a more integrated approach to decision-making, where procurement teams consider not only immediate cost but also clinical performance, patient experience, and long-term system impact. By supporting the adoption of purpose-built, regulated solutions, healthcare organizations can move toward greater consistency in airway management, contributing to improved outcomes across diverse care settings.

    Source link